An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.Most doses of Eli Lilly's highly popular weight loss drug Zepbound and diabetes counterpart Mounjaro will be in short supply through the second quarter of this year as demand jumps, according to an update on the Food and Drug Administration's drug shortage database on Wednesday. All doses of Zepbound and Mounjaro besides the 2.5-milligram versions of both treatments are in shortage. A previous ...

ToplineA late-stage trial of Eli Lilly’s weight loss drug Zepbound showed promising results in treating sleep apnea symptoms in obese adults, the company announced Wednesday, the latest findings suggesting popular weight loss drugs have the potential to treat conditions other than obesity or type 2 diabetes.Participants across two studies lost about 20% of their body weight while using the drug. NurPhoto via Getty Images Key FactsParticipants across two studies who used Zepbound experienced fewer AHI events ...

Core Viewpoint - Eli Lilly's weight loss drug Mounjaro has shown positive results in reducing irregular breathing in patients with obstructive sleep apnea, contributing to a 2.8% increase in stock price to $767.65 [1] Stock Performance - The stock is poised to end a four-day losing streak and has a remarkable 106.1% year-over-year gain [1] - Shares reached an all-time high of $800.78 on March 4, with support at the $730 level since early February [1] Options Trading Activity - Short-term options traders are predominantly bullish, with a Schaeffer's put/call open interest ratio (SOIR) of 0.62, ranking in the low 9th percentile of annual readings [1] - Current options volume is double the intraday average, with 10,000 calls and 6,250 puts traded so far [1] - The most active contract is the April 750 put, closely followed by the 470 call in the same series, both set to expire later this week [1]

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.Eli Lilly on Wednesday said its highly popular weight loss drug Zepbound showed the potential to treat patients with the most common sleep-related breathing disorder in two late-stage clinical trials.The initial results add to the long list of potential health benefits of weight loss and diabetes treatments, which have skyrocketed in demand over the last year despite their high prices and spott ...

Tirzepatide achieved a mean apnea-hypopnea index reduction of up to 63% (about 30 fewer events per hour), meeting all primary and key secondary endpoints in two phase 3 clinical trials Tirzepatide meaningfully improved sleep apnea symptoms in those with moderate-to-severe OSA and obesity with and without PAP therapy, and based on these results Lilly plans to submit these data for global regulatory reviews INDIANAPOLIS, April 17, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positiv ...

Eli Lilly (LLY) closed the latest trading day at $749.26, indicating a -0.2% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.03%. Elsewhere, the Dow saw an upswing of 0.41%, while the tech-heavy Nasdaq appreciated by 0.12%.Shares of the drugmaker witnessed a loss of 1.56% over the previous month, beating the performance of the Medical sector with its loss of 5.81% and underperforming the S&P 500's loss of 0.9%.The upcoming earnings release of Eli Lil ...

INDIANAPOLIS, April 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2024 financial results on April 30, 2024. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://inv ...

Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024.European Union drug regulators found no evidence that highly popular weight loss and diabetes drugs such as Wegovy and Ozempic are linked to an increased risk of suicidal thoughts and self-injury, the regulator said Friday. The European Medicines Agency conducted a nine-month investigation into so-called GLP-1s, a blockbuster class of treatments that mimic a hormone produced in the gut to suppress a person's appetit ...

These companies are close to launching new products that could supercharge revenue.Eli Lilly shares have soared more than 100% over the past year, bringing the company to a market value of more than $740 billion. Investors are excited about the pharma company because of its dominance in the billion-dollar weight loss drug market. Lilly sells two weight-loss drugs that, together, are bringing in billions of dollars in revenue, and demand for the products has even outpaced supply.If you've missed out on Lilly ...